1.
Full Text
Response: High Blood Pressure in Acute Stroke and Subsequent Outcome: A Systematic Review
Hypertension, ISSN 0194-911X, 01/2019, Issue 1
Journal Article
Stroke, ISSN 0039-2499, 03/2009, Volume 40, Issue 3, pp. E50 - E52
Background and Purpose - As a research community, we have failed to demonstrate that drugs which show substantial efficacy in animal models of cerebral...
RANDOMIZED CONTROLLED-TRIALS | IMPROVE | animal models | education | QUALITY | METAANALYSIS | drug trials | experimental | ACUTE STROKE TRIALS | basic science | preventing bias | outcomes | CONSORT STATEMENT | DRUGS | translational research | CLINICAL NEUROLOGY | PERIPHERAL VASCULAR DISEASE | Sample Size | Animals | Bias | Drug Industry | Humans | Research Design - standards | Treatment Outcome | Stroke - drug therapy | Conflict of Interest | Random Allocation | Disease Models, Animal | Research Support as Topic
RANDOMIZED CONTROLLED-TRIALS | IMPROVE | animal models | education | QUALITY | METAANALYSIS | drug trials | experimental | ACUTE STROKE TRIALS | basic science | preventing bias | outcomes | CONSORT STATEMENT | DRUGS | translational research | CLINICAL NEUROLOGY | PERIPHERAL VASCULAR DISEASE | Sample Size | Animals | Bias | Drug Industry | Humans | Research Design - standards | Treatment Outcome | Stroke - drug therapy | Conflict of Interest | Random Allocation | Disease Models, Animal | Research Support as Topic
Journal Article
Circulation, ISSN 0009-7322, 10/2013, Volume 128, Issue 15, pp. 1656 - 1666
BACKGROUND—Emerging studies suggest that early administration of dual antiplatelet therapy may be better than monotherapy for prevention of early recurrent...
Review, systematic | Stroke | Transient ischemic attack | Antiplatelet agents | Meta-analysis | ACETYLSALICYLIC-ACID | antiplatelet agents | CARDIAC & CARDIOVASCULAR SYSTEMS | meta-analysis | transient ischemic attack | systematic | stroke | ASPIRIN | SECONDARY PREVENTION | HIGH-RISK PATIENTS | CLOPIDOGREL | review | PLUS DIPYRIDAMOLE | MINOR STROKE | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | RECURRENT STROKE | Brain Ischemia - epidemiology | Ischemic Attack, Transient - epidemiology | Acute Disease | Ischemic Attack, Transient - drug therapy | Brain Ischemia - drug therapy | Humans | Risk Factors | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Randomized Controlled Trials as Topic | Stroke (Disease) | Aggregation | Care and treatment | Cerebral ischemia | Usage | Blood platelets | Analysis | Health aspects
Review, systematic | Stroke | Transient ischemic attack | Antiplatelet agents | Meta-analysis | ACETYLSALICYLIC-ACID | antiplatelet agents | CARDIAC & CARDIOVASCULAR SYSTEMS | meta-analysis | transient ischemic attack | systematic | stroke | ASPIRIN | SECONDARY PREVENTION | HIGH-RISK PATIENTS | CLOPIDOGREL | review | PLUS DIPYRIDAMOLE | MINOR STROKE | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | RECURRENT STROKE | Brain Ischemia - epidemiology | Ischemic Attack, Transient - epidemiology | Acute Disease | Ischemic Attack, Transient - drug therapy | Brain Ischemia - drug therapy | Humans | Risk Factors | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Randomized Controlled Trials as Topic | Stroke (Disease) | Aggregation | Care and treatment | Cerebral ischemia | Usage | Blood platelets | Analysis | Health aspects
Journal Article
Stroke, ISSN 0039-2499, 06/2008, Volume 39, Issue 6, pp. 1821 - 1826
Background and Purpose-An early and reliable prognosis for recovery in stroke patients is important for initiation of individual treatment and for informing...
Clinical trials | Soke | National Institutes of Health Stroke Scale | Outcome | Prediction | PROGNOSTIC MODELS | EXTERNAL VALIDATION | stroke | CLINICAL NEUROLOGY | BREAST-CANCER | THERAPY | prediction | DESMOTEPLASE | PERIPHERAL VASCULAR DISEASE | clinical trials | SCALE | outcome | ONSET | Brain Ischemia - epidemiology | Severity of Illness Index | Predictive Value of Tests | Data Interpretation, Statistical | Prognosis | Humans | Middle Aged | Stroke Rehabilitation | Male | Controlled Clinical Trials as Topic - statistics & numerical data | Models, Statistical | Survival | Brain Ischemia - rehabilitation | Aged, 80 and over | Female | Stroke - epidemiology | Aged | Databases, Factual
Clinical trials | Soke | National Institutes of Health Stroke Scale | Outcome | Prediction | PROGNOSTIC MODELS | EXTERNAL VALIDATION | stroke | CLINICAL NEUROLOGY | BREAST-CANCER | THERAPY | prediction | DESMOTEPLASE | PERIPHERAL VASCULAR DISEASE | clinical trials | SCALE | outcome | ONSET | Brain Ischemia - epidemiology | Severity of Illness Index | Predictive Value of Tests | Data Interpretation, Statistical | Prognosis | Humans | Middle Aged | Stroke Rehabilitation | Male | Controlled Clinical Trials as Topic - statistics & numerical data | Models, Statistical | Survival | Brain Ischemia - rehabilitation | Aged, 80 and over | Female | Stroke - epidemiology | Aged | Databases, Factual
Journal Article
Stroke, ISSN 0039-2499, 04/2012, Volume 43, Issue 4, pp. 1058 - 1066
Background and Purpose-Antiplatelets are recommended for patients with acute noncardioembolic stroke or transient ischemic attack. We compared the safety and...
cardiovascular prevention | transient ischemic attack | antiplatelet therapy | acute ischemic stroke | ACETYLSALICYLIC-ACID | EARLY RISK | VASCULAR EVENTS | ASPIRIN | SECONDARY PREVENTION | CLINICAL NEUROLOGY | CLOPIDOGREL | PLUS DIPYRIDAMOLE | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | THROMBOLYTIC THERAPY | CEREBRAL-ISCHEMIA | Recurrence | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Male | Aspirin - administration & dosage | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Aged, 80 and over | Dipyridamole - adverse effects | Ticlopidine - administration & dosage | Adult | Female | Drug Therapy, Combination | Databases, Factual | Platelet Aggregation Inhibitors - adverse effects | Stroke | Survival Rate | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Disease-Free Survival | Acute Coronary Syndrome - chemically induced | Aged | Brain Ischemia - mortality | Dipyridamole - administration & dosage
cardiovascular prevention | transient ischemic attack | antiplatelet therapy | acute ischemic stroke | ACETYLSALICYLIC-ACID | EARLY RISK | VASCULAR EVENTS | ASPIRIN | SECONDARY PREVENTION | CLINICAL NEUROLOGY | CLOPIDOGREL | PLUS DIPYRIDAMOLE | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | THROMBOLYTIC THERAPY | CEREBRAL-ISCHEMIA | Recurrence | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Male | Aspirin - administration & dosage | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Aged, 80 and over | Dipyridamole - adverse effects | Ticlopidine - administration & dosage | Adult | Female | Drug Therapy, Combination | Databases, Factual | Platelet Aggregation Inhibitors - adverse effects | Stroke | Survival Rate | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Disease-Free Survival | Acute Coronary Syndrome - chemically induced | Aged | Brain Ischemia - mortality | Dipyridamole - administration & dosage
Journal Article
Stroke, ISSN 0039-2499, 06/2007, Volume 38, Issue 6, pp. 1911 - 1915
Background and Purpose - Most large acute stroke trials have been neutral. Functional outcome is usually analyzed using a yes or no answer, eg, death or...
Stroke | Statistical analysis | Randomised controlled trial | OCCUPATIONAL-THERAPY | SAMPLE-SIZE CALCULATIONS | randomised controlled trial | stroke | RANTTAS | CLINICAL NEUROLOGY | EARLY ASPIRIN USE | ACUTE ISCHEMIC-STROKE | TIRILAZAD MESYLATE | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | statistical analysis | THROMBOLYTIC THERAPY | ECASS-II | Randomized Controlled Trials as Topic - statistics & numerical data | Humans | Recovery of Function - physiology | Stroke Rehabilitation | Stroke - epidemiology | Treatment Outcome | Models, Statistical
Stroke | Statistical analysis | Randomised controlled trial | OCCUPATIONAL-THERAPY | SAMPLE-SIZE CALCULATIONS | randomised controlled trial | stroke | RANTTAS | CLINICAL NEUROLOGY | EARLY ASPIRIN USE | ACUTE ISCHEMIC-STROKE | TIRILAZAD MESYLATE | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | statistical analysis | THROMBOLYTIC THERAPY | ECASS-II | Randomized Controlled Trials as Topic - statistics & numerical data | Humans | Recovery of Function - physiology | Stroke Rehabilitation | Stroke - epidemiology | Treatment Outcome | Models, Statistical
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2018, Volume 84, Issue 12, pp. 2914 - 2922
Aims Although high blood pressure (BP) is common in acute stroke and associated with poor outcome, the Efficacy of Nitric Oxide in Stroke (ENOS) trial showed...
blood pressure | intracerebral haemorrhage | ischaemic stroke | dehydration | acute stroke | glyceryl trinitrate | MORTALITY | INDEPENDENT PREDICTOR | MANAGEMENT | EFFICACY | GUIDELINES | HEALTH-CARE PROFESSIONALS | ENOS | RENAL DYSFUNCTION | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | Hypertension | Medical research | Prognosis | Nitrates | Stroke (Disease) | Urea | Nitric oxide | Analysis | Medicine, Experimental | Antihypertensive drugs | Blood pressure | Drug therapy | Dehydration (Physiology) | Original
blood pressure | intracerebral haemorrhage | ischaemic stroke | dehydration | acute stroke | glyceryl trinitrate | MORTALITY | INDEPENDENT PREDICTOR | MANAGEMENT | EFFICACY | GUIDELINES | HEALTH-CARE PROFESSIONALS | ENOS | RENAL DYSFUNCTION | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | Hypertension | Medical research | Prognosis | Nitrates | Stroke (Disease) | Urea | Nitric oxide | Analysis | Medicine, Experimental | Antihypertensive drugs | Blood pressure | Drug therapy | Dehydration (Physiology) | Original
Journal Article
Stroke, ISSN 0039-2499, 02/2012, Volume 43, Issue 2, pp. 405 - 411
Background and Purpose-Granulocyte-colony stimulating factor (G-CSF) is neuroprotective in experimental stroke and mobilizes CD34(+) peripheral blood stem...
hematopoietic stem cell | stroke recovery | granulocyte colony-stimulating factor | CD34 | PROGENITOR CELLS | PERIPHERAL VASCULAR DISEASE | G-CSF | ISCHEMIC-STROKE | CLINICAL NEUROLOGY | Antigens, CD34 | Brain Ischemia - complications | Brain - cytology | Prospective Studies | Double-Blind Method | Hematopoietic Stem Cell Mobilization - methods | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Recovery of Function | Echo-Planar Imaging | Fibrinolytic Agents - therapeutic use | Lymphocyte Count | Bone Marrow Cells - drug effects | Female | Aged | Cerebral Hemorrhage - complications | Receptors, Granulocyte Colony-Stimulating Factor - therapeutic use | Stroke - therapy
hematopoietic stem cell | stroke recovery | granulocyte colony-stimulating factor | CD34 | PROGENITOR CELLS | PERIPHERAL VASCULAR DISEASE | G-CSF | ISCHEMIC-STROKE | CLINICAL NEUROLOGY | Antigens, CD34 | Brain Ischemia - complications | Brain - cytology | Prospective Studies | Double-Blind Method | Hematopoietic Stem Cell Mobilization - methods | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Recovery of Function | Echo-Planar Imaging | Fibrinolytic Agents - therapeutic use | Lymphocyte Count | Bone Marrow Cells - drug effects | Female | Aged | Cerebral Hemorrhage - complications | Receptors, Granulocyte Colony-Stimulating Factor - therapeutic use | Stroke - therapy
Journal Article
Hypertension, ISSN 0194-911X, 10/2009, Volume 54, Issue 4, pp. 775 - 781
Both low and high blood pressures (BPs) during the acute phase of stroke are associated independently with a poor outcome. Several small clinical trials have...
Randomized, controlled trial | Blood pressure | Metaregression | Acute stroke | blood pressure | CEREBRAL GLUCOSE-METABOLISM | QUALITY-OF-CARE | BLIND CONTROLLED-TRIAL | HYPERVOLEMIC HEMODILUTION | RANDOMIZED CONTROLLED-TRIAL | INTRAVENOUS MAGNESIUM-SULFATE | acute stroke | APTIGANEL HYDROCHLORIDE | randomized, controlled trial | ACUTE ISCHEMIC-STROKE | metaregression | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | ACUTE NONHEMORRHAGIC STROKE | Prognosis | Age Factors | Follow-Up Studies | Humans | Middle Aged | Stroke - diagnosis | Hypertension - drug therapy | Male | Stroke - physiopathology | Hypertension - physiopathology | Contraindications | Regression Analysis | Aged, 80 and over | Adult | Female | Aged | Blood Pressure - physiology | Antihypertensive Agents
Randomized, controlled trial | Blood pressure | Metaregression | Acute stroke | blood pressure | CEREBRAL GLUCOSE-METABOLISM | QUALITY-OF-CARE | BLIND CONTROLLED-TRIAL | HYPERVOLEMIC HEMODILUTION | RANDOMIZED CONTROLLED-TRIAL | INTRAVENOUS MAGNESIUM-SULFATE | acute stroke | APTIGANEL HYDROCHLORIDE | randomized, controlled trial | ACUTE ISCHEMIC-STROKE | metaregression | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | ACUTE NONHEMORRHAGIC STROKE | Prognosis | Age Factors | Follow-Up Studies | Humans | Middle Aged | Stroke - diagnosis | Hypertension - drug therapy | Male | Stroke - physiopathology | Hypertension - physiopathology | Contraindications | Regression Analysis | Aged, 80 and over | Adult | Female | Aged | Blood Pressure - physiology | Antihypertensive Agents
Journal Article
Molecular and Cellular Neuroscience, ISSN 1044-7431, 11/2015, Volume 69, p. 65
Cerebral ischaemia, associated with neuroinflammation and oxidative stress, is known to perturb blood-brain barrier (BBB) integrity and promote brain oedema...
Oxidases | Tumor necrosis factor | Analysis | Brain damage | Glucose | Muscle proteins | Dextrose
Oxidases | Tumor necrosis factor | Analysis | Brain damage | Glucose | Muscle proteins | Dextrose
Journal Article
Stroke, ISSN 0039-2499, 08/2012, Volume 43, Issue 8
Journal Article
Stroke, ISSN 0039-2499, 12/2013, Volume 44, Issue 12, pp. 3458 - 3462
BACKGROUND AND PURPOSE—Health-related quality of life, a key outcome after stroke, plays a role in the analysis of treatment cost-effectiveness. Some measures...
Stroke | Outcome assessment (health care) | Health care economics and organizations | Quality of life | DEPRESSION | TAIST | EUROQOL | stroke | HEALTH STATES | CLINICAL NEUROLOGY | THERAPY | health care economics and organizations | outcome assessment (health care) | ACUTE ISCHEMIC-STROKE | DISABILITY | PERIPHERAL VASCULAR DISEASE | CEREBRAL INFARCTION | SCALE | quality of life | TINZAPARIN | Activities of Daily Living - psychology | Age Factors | Outcome Assessment (Health Care) | Stroke - psychology | Humans | Middle Aged | Male | Treatment Outcome | Disabled Persons - psychology | Sex Factors | Aged, 80 and over | Depression - psychology | Female | Surveys and Questionnaires | Aged | Quality of Life - psychology | Health Status
Stroke | Outcome assessment (health care) | Health care economics and organizations | Quality of life | DEPRESSION | TAIST | EUROQOL | stroke | HEALTH STATES | CLINICAL NEUROLOGY | THERAPY | health care economics and organizations | outcome assessment (health care) | ACUTE ISCHEMIC-STROKE | DISABILITY | PERIPHERAL VASCULAR DISEASE | CEREBRAL INFARCTION | SCALE | quality of life | TINZAPARIN | Activities of Daily Living - psychology | Age Factors | Outcome Assessment (Health Care) | Stroke - psychology | Humans | Middle Aged | Male | Treatment Outcome | Disabled Persons - psychology | Sex Factors | Aged, 80 and over | Depression - psychology | Female | Surveys and Questionnaires | Aged | Quality of Life - psychology | Health Status
Journal Article
Stroke, ISSN 0039-2499, 10/2013, Volume 44, Issue 10, pp. 2755 - 2759
Background and Purpose The ischemic stroke risk score (iScore) is a validated tool developed to estimate the risk of death and functional outcomes early after...
Predicting score | Prognosis | Iscore | Outcomes | SCORE | iScore | TISSUE-PLASMINOGEN ACTIVATOR | HEMORRHAGE | predicting score | PROGNOSTIC MODELS | EXTERNAL VALIDATION | prognosis | CLINICAL NEUROLOGY | THERAPY | outcomes | ACUTE ISCHEMIC-STROKE | IMPROVEMENT | PERIPHERAL VASCULAR DISEASE | SCALE | ASSOCIATION | Predictive Value of Tests | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Clinical Trials as Topic | Stroke - drug therapy | Tissue Plasminogen Activator - therapeutic use | Models, Biological | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Thrombolytic Therapy | Aged, 80 and over | Female | Aged | Brain Ischemia - mortality | Internet | Stroke - mortality | Databases, Factual
Predicting score | Prognosis | Iscore | Outcomes | SCORE | iScore | TISSUE-PLASMINOGEN ACTIVATOR | HEMORRHAGE | predicting score | PROGNOSTIC MODELS | EXTERNAL VALIDATION | prognosis | CLINICAL NEUROLOGY | THERAPY | outcomes | ACUTE ISCHEMIC-STROKE | IMPROVEMENT | PERIPHERAL VASCULAR DISEASE | SCALE | ASSOCIATION | Predictive Value of Tests | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Clinical Trials as Topic | Stroke - drug therapy | Tissue Plasminogen Activator - therapeutic use | Models, Biological | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Thrombolytic Therapy | Aged, 80 and over | Female | Aged | Brain Ischemia - mortality | Internet | Stroke - mortality | Databases, Factual
Journal Article
Stroke, ISSN 0039-2499, 11/2013, Volume 44, Issue 11, pp. e144 - e145
Journal Article
Stroke, ISSN 0039-2499, 11/2009, Volume 40, Issue 11, pp. 3541 - 3546
BACKGROUND AND PURPOSE—High blood pressure (BP) is common in acute ischemic stroke and associated independently with a poor functional outcome. However, the...
Blood pressure | Ischemic stroke | Randomized controlled trial | Acute stroke | Outcome | Telmisartan | blood pressure | telmisartan | FLOW | CLINICAL NEUROLOGY | randomized controlled trial | TRIAL | acute stroke | CLOPIDOGREL | INTRAVENOUS NIMODIPINE | PERIPHERAL VASCULAR DISEASE | EXTENDED-RELEASE DIPYRIDAMOLE | ischemic stroke | outcome | Stroke - prevention & control | Benzoates - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Hypertension - drug therapy | Male | Brain Ischemia - physiopathology | Brain Ischemia - prevention & control | Secondary Prevention | Stroke - drug therapy | Stroke - physiopathology | Hypertension - physiopathology | Brain Ischemia - drug therapy | Hypertension - prevention & control | Female | Aged | Blood Pressure - drug effects | Blood Pressure - physiology | Benzimidazoles - therapeutic use
Blood pressure | Ischemic stroke | Randomized controlled trial | Acute stroke | Outcome | Telmisartan | blood pressure | telmisartan | FLOW | CLINICAL NEUROLOGY | randomized controlled trial | TRIAL | acute stroke | CLOPIDOGREL | INTRAVENOUS NIMODIPINE | PERIPHERAL VASCULAR DISEASE | EXTENDED-RELEASE DIPYRIDAMOLE | ischemic stroke | outcome | Stroke - prevention & control | Benzoates - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Hypertension - drug therapy | Male | Brain Ischemia - physiopathology | Brain Ischemia - prevention & control | Secondary Prevention | Stroke - drug therapy | Stroke - physiopathology | Hypertension - physiopathology | Brain Ischemia - drug therapy | Hypertension - prevention & control | Female | Aged | Blood Pressure - drug effects | Blood Pressure - physiology | Benzimidazoles - therapeutic use
Journal Article
Stroke, ISSN 0039-2499, 04/2010, Volume 41, Issue 4, pp. 732 - 738
Background and Purpose-Long-term antiplatelet therapy is effective at reducing recurrence after ischemic stroke. However, the relative safety and efficacy of...
Aspirin | Acute stroke | Outcome | Dipyridamole | Clopidogrel | Ischemic stroke | Randomized controlled trial | clopidogrel | EVENTS | RANDOMIZED CONTROLLED-TRIAL | ANTIPLATELET THERAPY | SECONDARY PREVENTION | CLINICAL NEUROLOGY | randomized controlled trial | TELMISARTAN | HIGH-RISK PATIENTS | acute stroke | dipyridamole | DOUBLE-BLIND | aspirin | ATTACK | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | CEREBRAL-ISCHEMIA | ischemic stroke | outcome | Stroke - prevention & control | Ticlopidine - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Brain Ischemia - prevention & control | Secondary Prevention | Stroke - drug therapy | Recovery of Function | Ticlopidine - analogs & derivatives | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Female | Aged | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use
Aspirin | Acute stroke | Outcome | Dipyridamole | Clopidogrel | Ischemic stroke | Randomized controlled trial | clopidogrel | EVENTS | RANDOMIZED CONTROLLED-TRIAL | ANTIPLATELET THERAPY | SECONDARY PREVENTION | CLINICAL NEUROLOGY | randomized controlled trial | TELMISARTAN | HIGH-RISK PATIENTS | acute stroke | dipyridamole | DOUBLE-BLIND | aspirin | ATTACK | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | CEREBRAL-ISCHEMIA | ischemic stroke | outcome | Stroke - prevention & control | Ticlopidine - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Brain Ischemia - prevention & control | Secondary Prevention | Stroke - drug therapy | Recovery of Function | Ticlopidine - analogs & derivatives | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Female | Aged | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use
Journal Article
Stroke, ISSN 0039-2499, 01/2005, Volume 36, Issue 1, pp. 162 - 168
Background and Purpose - Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic...
Aspirin | Stroke prevention | Transient ischemic attack | Dipyridamole | ARTERIAL | dipyridamole | aspirin | EUROPEAN STROKE | PERIPHERAL VASCULAR DISEASE | transient ischemic attack | DOSE ACETYLSALICYLIC-ACID | stroke prevention | SECONDARY PREVENTION | CLINICAL NEUROLOGY | Brain Ischemia - epidemiology | Myocardial Infarction - epidemiology | Stroke - prevention & control | Humans | Middle Aged | Stroke - diagnosis | Male | Treatment Outcome | Brain Ischemia - prevention & control | Secondary Prevention | Randomized Controlled Trials as Topic | Ischemic Attack, Transient - epidemiology | Ischemic Attack, Transient - prevention & control | Aspirin - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Aspirin - therapeutic use | Blood Pressure - drug effects | Myocardial Infarction - prevention & control | Drug Therapy, Combination | Dipyridamole - therapeutic use
Aspirin | Stroke prevention | Transient ischemic attack | Dipyridamole | ARTERIAL | dipyridamole | aspirin | EUROPEAN STROKE | PERIPHERAL VASCULAR DISEASE | transient ischemic attack | DOSE ACETYLSALICYLIC-ACID | stroke prevention | SECONDARY PREVENTION | CLINICAL NEUROLOGY | Brain Ischemia - epidemiology | Myocardial Infarction - epidemiology | Stroke - prevention & control | Humans | Middle Aged | Stroke - diagnosis | Male | Treatment Outcome | Brain Ischemia - prevention & control | Secondary Prevention | Randomized Controlled Trials as Topic | Ischemic Attack, Transient - epidemiology | Ischemic Attack, Transient - prevention & control | Aspirin - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Aspirin - therapeutic use | Blood Pressure - drug effects | Myocardial Infarction - prevention & control | Drug Therapy, Combination | Dipyridamole - therapeutic use
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 10, p. CD000039
Background It is unclear whether blood pressure should be altered actively during the acute phase of stroke. This is an update of a Cochrane review first...
Acute Disease | Hypertension [drug therapy] | Humans | Vasodilator Agents [therapeutic use] | Risk | RANDOMIZED-TRIAL | ACUTE INTRACEREBRAL HEMORRHAGE | Calcium Channel Blockers [therapeutic use] | HEALTH-CARE PROFESSIONALS | SECONDARY PREVENTION | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Blood Pressure [drug effects] | INTRAVENOUS NIMODIPINE | ACUTE ISCHEMIC-STROKE | DOUBLE-BLIND | Stroke [physiopathology; prevention & control] | CEREBRAL-HEMORRHAGE TRIAL | PLACEBO-CONTROLLED TRIAL | HEMATOMA ENLARGEMENT | Stroke - prevention & control | Time-to-Treatment - statistics & numerical data | Vasodilator Agents - therapeutic use | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Blood Pressure - drug effects | Stroke - physiopathology
Acute Disease | Hypertension [drug therapy] | Humans | Vasodilator Agents [therapeutic use] | Risk | RANDOMIZED-TRIAL | ACUTE INTRACEREBRAL HEMORRHAGE | Calcium Channel Blockers [therapeutic use] | HEALTH-CARE PROFESSIONALS | SECONDARY PREVENTION | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Blood Pressure [drug effects] | INTRAVENOUS NIMODIPINE | ACUTE ISCHEMIC-STROKE | DOUBLE-BLIND | Stroke [physiopathology; prevention & control] | CEREBRAL-HEMORRHAGE TRIAL | PLACEBO-CONTROLLED TRIAL | HEMATOMA ENLARGEMENT | Stroke - prevention & control | Time-to-Treatment - statistics & numerical data | Vasodilator Agents - therapeutic use | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Blood Pressure - drug effects | Stroke - physiopathology
Journal Article
Stroke, ISSN 0039-2499, 08/2012, Volume 43, Issue 8, pp. e71 - E71
Journal Article
Stroke, ISSN 0039-2499, 03/2011, Volume 42, Issue 3, pp. 650 - 655
Background and Purpose-After stroke and transient ischemic attack there is a high early risk of recurrent stroke, particularly in large artery disease. It has...
carotid stenosis | embolism | antiplatelet | stroke | prevention | ultrasound | RISK | PERIPHERAL VASCULAR DISEASE | EMBOLIC SIGNAL-DETECTION | ANTIPLATELET THERAPY | CLINICAL NEUROLOGY | Double-Blind Method | Follow-Up Studies | Stroke - diagnostic imaging | Humans | Middle Aged | Ambulatory Care - methods | Male | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aspirin - administration & dosage | Ultrasonography, Doppler, Transcranial - methods | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Aged | Dipyridamole - administration & dosage | Drug Therapy, Combination
carotid stenosis | embolism | antiplatelet | stroke | prevention | ultrasound | RISK | PERIPHERAL VASCULAR DISEASE | EMBOLIC SIGNAL-DETECTION | ANTIPLATELET THERAPY | CLINICAL NEUROLOGY | Double-Blind Method | Follow-Up Studies | Stroke - diagnostic imaging | Humans | Middle Aged | Ambulatory Care - methods | Male | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aspirin - administration & dosage | Ultrasonography, Doppler, Transcranial - methods | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Aged | Dipyridamole - administration & dosage | Drug Therapy, Combination
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.